AXSM Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 22.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $10,005,148.57

Axsome Therapeutics Insider Trading History Chart

Axsome Therapeutics Share Price & Price History

^$95.06

▲ +0.46 (0.49%)

As of 11/21/2024 10:44 AM ET

Days: 30 | 90 | 365

Breaking News: Tesla headed to $500…

From WealthPress | Ad

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

Axsome Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/11/2024	Mark E. Saad	Director	Sell	11,016	$91.31	$1,005,870.96	10,002
8/9/2024	Mark L. Jacobson	COO	Sell	47,739	$84.26	$4,022,488.14	5,783
5/29/2024	Mark L. Jacobson	COO	Sell	7,910	$74.31	$587,792.10	5,783
5/28/2024	Mark Coleman	Director	Sell	5,249	$75.21	$394,777.29	19,848
4/1/2024	Mark L. Jacobson	COO	Sell	24,662	$77.24	$1,904,892.88
3/14/2024	Roger Jeffs	Director	Sell	29,976	$69.70	$2,089,327.20	120,756
9/15/2023	Mark Coleman	Director	Sell	11,016	$75.19	$828,293.04	25,097
11/19/2021	Roger Jeffs	Director	Buy	3,950	$37.30	$147,335.00
11/18/2021	Nick Pizzie	CFO	Buy	527	$35.50	$18,708.50

Breaking News: Tesla headed to $500…

From WealthPress | Ad

That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla.

So to claim your free digital copy today, simply follow this link and enter your email address.

SEC Filings (Institutional Ownership Changes) for Axsome Therapeutics (NASDAQ:AXSM)

81.49% of Axsome Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Axsome Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/16/2024	Geode Capital Management LLC	908,459	$81.66M	0.0%	+2.7%	1.875%
11/15/2024	Barclays PLC	61,785	$5.55M	0.0%	+279.6%	0.127%
11/15/2024	Y Intercept Hong Kong Ltd	7,958	$0.72M	0.0%	-31.2%	0.016%
11/15/2024	Wellington Management Group LLP	742,745	$66.75M	0.0%	+1.1%	1.533%
11/15/2024	State Street Corp	916,808	$82.39M	0.0%	-2.3%	1.892%
11/15/2024	Quarry LP	2,000	$0.18M	0.0%	-37.5%	0.004%
11/15/2024	RTW Investments LP	4,189,557	$376.52M	5.4%	-9.6%	8.645%
11/15/2024	Iron Triangle Partners LP	252,266	$22.67M	3.1%	N/A	0.521%
11/15/2024	HighVista Strategies LLC	41,542	$3.73M	1.3%	-33.2%	0.086%
11/15/2024	Checkpoint Capital L.P.	209,632	$18.84M	9.3%	-27.9%	0.433%
11/15/2024	Alethea Capital Management LLC	738,503	$66.37M	47.9%	-0.3%	1.555%
11/15/2024	Erste Asset Management GmbH	11,000	$0.99M	0.0%	N/A	0.023%
11/14/2024	Bellevue Group AG	367,181	$33M	0.5%	-28.9%	0.773%
11/14/2024	Point72 Europe London LLP	34,570	$3.11M	0.2%	+12.5%	0.073%
11/14/2024	PDT Partners LLC	11,701	$1.05M	0.1%	N/A	0.025%
11/14/2024	Fred Alger Management LLC	9,466	$0.85M	0.0%	N/A	0.020%
11/14/2024	Eventide Asset Management LLC	827,887	$74.40M	1.3%	-11.8%	1.743%
11/14/2024	Captrust Financial Advisors	5,722	$0.51M	0.0%	N/A	0.012%
11/14/2024	UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	47,714	$4.29M	0.0%	-15.1%	0.100%
11/14/2024	PEAK6 Investments LLC	3,760	$0.34M	0.0%	-49.9%	0.008%
11/14/2024	FORA Capital LLC	11,058	$0.99M	0.1%	N/A	0.023%
11/13/2024	Cynosure Group LLC	7,930	$0.71M	0.1%	N/A	0.017%
11/13/2024	BNP Paribas Financial Markets	13,733	$1.23M	0.0%	+71.7%	0.029%
11/13/2024	FMR LLC	1,088,087	$97.79M	0.0%	+20.6%	2.291%
11/13/2024	D.A. Davidson & CO.	8,160	$0.73M	0.0%	-13.3%	0.017%
11/13/2024	The Manufacturers Life Insurance Company	22,623	$2.03M	0.0%	-1.2%	0.048%
11/13/2024	Loomis Sayles & Co. L P	298,586	$26.83M	0.0%	+11.0%	0.629%
11/12/2024	Pitcairn Co.	4,414	$0.40M	0.0%	-11.3%	0.009%
11/12/2024	Eagle Asset Management Inc.	82,791	$7.46M	0.0%	-16.1%	0.174%
11/12/2024	Charles Schwab Investment Management Inc.	322,596	$28.99M	0.0%	+4.1%	0.679%
11/9/2024	Landscape Capital Management L.L.C.	6,513	$0.59M	0.1%	N/A	0.014%
11/9/2024	Intech Investment Management LLC	10,941	$0.98M	0.0%	N/A	0.023%
11/8/2024	Moors & Cabot Inc.	2,230	$0.20M	0.0%	N/A	0.005%
11/8/2024	B. Metzler seel. Sohn & Co. Holding AG	9,241	$0.83M	0.0%	N/A	0.019%
11/8/2024	Phocas Financial Corp.	17,701	$1.59M	0.0%	-5.8%	0.037%
11/7/2024	Whalen Wealth Management Inc.	2,628	$0.24M	0.2%	N/A	0.006%
11/7/2024	First Turn Management LLC	255,294	$22.94M	3.6%	-24.3%	0.537%
11/6/2024	Mutual of America Capital Management LLC	39,522	$3.55M	0.0%	-0.9%	0.083%
11/6/2024	Royce & Associates LP	22,500	$2.02M	0.0%	+73.1%	0.047%
11/5/2024	WCM Investment Management LLC	113,692	$10.19M	0.0%	+0.3%	0.239%
11/4/2024	Versor Investments LP	8,807	$0.79M	0.1%	N/A	0.019%
11/4/2024	State of New Jersey Common Pension Fund D	22,411	$2.01M	0.0%	-9.4%	0.047%
11/2/2024	Privium Fund Management B.V.	80,232	$7.21M	1.8%	+7.9%	0.169%
11/1/2024	Lindbrook Capital LLC	64,707	$5.82M	0.5%	-8.0%	0.136%
10/31/2024	Principal Financial Group Inc.	3,393	$0.31M	0.0%	-48.2%	0.007%
10/30/2024	AlphaCentric Advisors LLC	10,500	$0.94M	0.7%	-30.0%	0.022%
10/29/2024	Old North State Wealth Management LLC	3,450	$0.31M	0.2%	-8.0%	0.007%
10/28/2024	Oak Ridge Investments LLC	13,417	$1.21M	0.1%	-3.7%	0.028%
10/28/2024	US Bancorp DE	133,126	$11.96M	0.0%	+0.3%	0.280%
10/25/2024	China Universal Asset Management Co. Ltd.	9,232	$0.83M	0.1%	+65.4%	0.019%
10/25/2024	abrdn plc	11,048	$0.99M	0.0%	-72.2%	0.023%
10/24/2024	Wealth Enhancement Advisory Services LLC	19,808	$1.78M	0.0%	+4.0%	0.042%
10/23/2024	Mirae Asset Global Investments Co. Ltd.	1,736	$0.16M	0.0%	+22.4%	0.004%
10/23/2024	Values First Advisors Inc.	6,322	$0.57M	0.3%	N/A	0.013%
10/23/2024	Assenagon Asset Management S.A.	4,483	$0.40M	0.0%	-86.8%	0.009%
10/23/2024	Moody Aldrich Partners LLC	60,644	$5.45M	1.0%	-1.8%	0.128%
10/23/2024	Hennion & Walsh Asset Management Inc.	58,148	$5.23M	0.2%	-10.1%	0.122%
10/11/2024	Creative Planning	10,854	$0.98M	0.0%	+29.8%	0.023%
10/8/2024	CWM LLC	20,793	$1.87M	0.0%	-13.1%	0.044%
10/5/2024	Handelsbanken Fonder AB	12,300	$1.11M	0.0%	+19.4%	0.026%
10/3/2024	SG Americas Securities LLC	11,553	$1.04M	0.0%	N/A	0.024%
9/16/2024	Point72 Asia Singapore Pte. Ltd.	584	$47K	0.0%	N/A	0.001%
8/27/2024	Clearbridge Investments LLC	106,767	$8.60M	0.0%	+19.5%	0.225%
8/27/2024	Dana Investment Advisors Inc.	19,724	$1.59M	0.1%	+3.7%	0.042%
8/26/2024	Teachers Retirement System of The State of Kentucky	11,354	$0.91M	0.0%	+17.1%	0.024%
8/16/2024	Perceptive Advisors LLC	459,111	$36.96M	0.9%	-58.5%	0.967%
8/16/2024	Quarry LP	3,200	$0.26M	0.1%	+77.8%	0.007%
8/16/2024	Northwestern Mutual Wealth Management Co.	335	$27K	0.0%	N/A	0.001%
8/16/2024	Creative Planning	8,365	$0.67M	0.0%	+15.9%	0.018%
8/16/2024	Algert Global LLC	3,105	$0.25M	0.0%	N/A	0.007%
8/15/2024	The Manufacturers Life Insurance Company	22,901	$1.84M	0.0%	+4.6%	0.048%
8/15/2024	Millennium Management LLC	739,819	$59.56M	0.0%	+1.4%	1.558%
8/15/2024	AQR Capital Management LLC	12,836	$1.03M	0.0%	-54.6%	0.027%
8/15/2024	Affinity Asset Advisors LLC	80,000	$6.44M	0.7%	-42.8%	0.168%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	584	$47K	0.0%	N/A	0.001%
8/15/2024	Point72 Europe London LLP	30,741	$2.48M	0.2%	N/A	0.065%
8/14/2024	Tri Locum Partners LP	306,513	$24.67M	6.2%	+198.4%	0.645%
8/14/2024	Bank of Montreal Can	10,531	$0.85M	0.0%	N/A	0.022%
8/14/2024	Hood River Capital Management LLC	549,066	$44.20M	0.9%	+5.4%	1.156%
8/14/2024	HighVista Strategies LLC	62,192	$5.01M	1.8%	+28.2%	0.131%
8/14/2024	ProShare Advisors LLC	7,707	$0.62M	0.0%	-20.7%	0.016%
8/14/2024	Profund Advisors LLC	6,871	$0.55M	0.0%	-23.8%	0.014%
8/13/2024	Sei Investments Co.	40,624	$3.27M	0.0%	+13.9%	0.086%
8/12/2024	XTX Topco Ltd	11,205	$0.90M	0.1%	+177.9%	0.024%
8/12/2024	Hsbc Holdings PLC	3,785	$0.30M	0.0%	-21.7%	0.008%
8/12/2024	Blair William & Co. IL	59,151	$4.76M	0.0%	-6.9%	0.125%
8/10/2024	Mutual of America Capital Management LLC	39,893	$3.21M	0.0%	-4.1%	0.084%
8/10/2024	Sofinnova Investments Inc.	310,198	$24.97M	1.3%	N/A	0.653%
8/9/2024	WINTON GROUP Ltd	8,823	$0.71M	0.0%	+156.6%	0.019%
8/8/2024	First Turn Management LLC	337,246	$27.15M	4.4%	-1.4%	0.710%
8/8/2024	State of New Jersey Common Pension Fund D	24,729	$1.99M	0.0%	-27.0%	0.052%
8/7/2024	Wedbush Securities Inc.	4,818	$0.39M	0.0%	-41.9%	0.010%
8/6/2024	Torray Investment Partners LLC	11,747	$0.95M	0.1%	+11.5%	0.025%
8/5/2024	Arizona State Retirement System	8,630	$0.70M	0.0%	+2.1%	0.018%
8/1/2024	Rhumbline Advisers	54,931	$4.42M	0.0%	+5.1%	0.116%
8/1/2024	Privium Fund Management B.V.	74,332	$5.87M	1.5%	-9.4%	0.156%
7/29/2024	Peregrine Capital Management LLC	87,373	$7.03M	0.2%	+1.4%	0.184%
7/29/2024	Principal Financial Group Inc.	6,554	$0.53M	0.0%	-32.9%	0.014%
7/26/2024	Iridian Asset Management LLC CT	126,905	$10.22M	2.3%	-1.5%	0.267%
7/26/2024	Bank of New York Mellon Corp	165,564	$13.33M	0.0%	+7.7%	0.349%

Data available starting January 2016

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Today's Range

Now: $95.06

$94.45

$95.25

50 Day Range

MA: $90.76

$83.08

$99.49

52 Week Range

Now: $95.06

$59.09

$105.00

Volume

8,324 shs

Average Volume

617,364 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Who are the company insiders with the largest holdings of Axsome Therapeutics?: Axsome Therapeutics' top insider investors include:
Roger Jeffs (Director)
Mark Coleman (Director)
Mark E Saad (Director)
Mark L Jacobson (COO)
Mark L Jacobson (COO)
Learn More about top insider investors at Axsome Therapeutics.
Who are the major institutional investors of Axsome Therapeutics?: Axsome Therapeutics' top institutional shareholders include:
RTW Investments LP — 8.65%
FMR LLC — 2.29%
State Street Corp — 1.89%
Geode Capital Management LLC — 1.87%
Eventide Asset Management LLC — 1.74%
Wellington Management Group LLP — 1.53%
Learn More about top institutional investors of Axsome Therapeutics stock.
Which institutional investors are selling Axsome Therapeutics stock?: During the last quarter, AXSM stock was sold by these institutional investors:
RTW Investments LP
Bellevue Group AG
Eventide Asset Management LLC
First Turn Management LLC
Checkpoint Capital L.P.
Assenagon Asset Management S.A.
abrdn plc
State Street Corp
During the last year, company insiders that have sold Axsome Therapeutics company stock include:
Roger Jeffs (Director)
Mark Coleman (Director)
Mark E Saad (Director)
Mark L Jacobson (COO)
Mark L Jacobson (COO)
Learn More investors selling Axsome Therapeutics stock.
Which institutional investors are buying Axsome Therapeutics stock?: Within the previous quarter, AXSM stock was bought by institutional investors including:
Iron Triangle Partners LP
FMR LLC
Jane Street Group LLC
Barclays PLC
Loomis Sayles & Co. L P
Geode Capital Management LLC
Charles Schwab Investment Management Inc.
PDT Partners LLC